Delineating the deranged immune system in the antiphospholipid syndrome

Autoimmunity Reviews

Volumn 15, Issue 1, 2016, Pages 50-60

  van den Hoogen, Lucas L ^a   van Roon, Joël A G ^a   Radstake, Timothy R D J ^a   Fritsch Stork, Ruth D E ^a   Derksen, Ronald H W M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

Anti 2 glycoprotein I antibody; Antiphospholipid syndrome; Autoreactive T cell; Dendritic cell; Monocyte; Neutrophil

Indexed keywords

PHOSPHOLIPID ANTIBODY;

ADAPTIVE IMMUNITY; ANTIPHOSPHOLIPID SYNDROME; AUTOIMMUNE DISEASE; B LYMPHOCYTE; COMPLEMENT SYSTEM; DENDRITIC CELL; ENVIRONMENTAL FACTOR; HEREDITY; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL; PATHOGENESIS; PATHOPHYSIOLOGY; PLASMACYTOID DENDRITIC CELL; REVIEW; T LYMPHOCYTE; ANIMAL; ANTIGEN PRESENTATION; GENETICS; IMMUNOLOGY;

ANIMALS; ANTIGEN PRESENTATION; ANTIPHOSPHOLIPID SYNDROME; B-LYMPHOCYTES; DENDRITIC CELLS; HUMANS; T-LYMPHOCYTES;

EID: 84955209070     PISSN: 15689972     EISSN: 18730183     Source Type: Journal    
DOI: 10.1016/j.autrev.2015.08.011     Document Type: Review

References (195)

1. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006, 4:295-306. 10.1111/j.1538-7836.2006.01753.x.
2. Abreu M.M., Danowski A., Wahl D.G., Amigo M.-C., Tektonidou M., Pacheco M.S., et al. The relevance of "non-criteria" clinical manifestations of antiphospholipid syndrome: 14th International Congress on Antiphospholipid Antibodies Technical Task Force Report on Antiphospholipid Syndrome Clinical Features. Autoimmun Rev 2015, 14:401-414. 10.1016/j.autrev.2015.01.002.
3. Denas G., Jose S.P., Bracco A., Zoppellaro G., Pengo V. Antiphospholipid syndrome and the heart: a case series and literature review. Autoimmun Rev 2015, 14:214-222. 10.1016/j.autrev.2014.11.003.
4. Bertolaccini M.L., Amengual O., Andreoli L., Atsumi T., Chighizola C.B., Forastiero R., et al. 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. Autoimmun Rev 2014, 13:917-930. 10.1016/j.autrev.2014.05.001.
5. Berman H., Rodríguez-Pintó I., Cervera R., Gregory S., de Meis E., Rodrigues C.E.M., et al. Pediatric catastrophic antiphospholipid syndrome: descriptive analysis of 45 patients from the "CAPS registry". Autoimmun Rev 2014, 13:157-162. 10.1016/j.autrev.2013.10.004.
6. Cervera R., Rodríguez-Pintó I., Colafrancesco S., Conti F., Valesini G., Rosário C., et al. 14Th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014, 13:699-707. 10.1016/j.autrev.2014.03.002.
7. De Laat B., Derksen R.H.W.M., De Groot P.G. B2-Glycoprotein I, the playmaker of the antiphospholipid syndrome. Clin Immunol 2004, 112:161-168. 10.1016/j.clim.2004.02.012.
8. Ağar Ç., Van Os G.M., Mörgelin M., Sprenger R.R., Marquart J.A., Urbanus R.T., et al. β2-Glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome. Blood 2010, 116:1336-1343. 10.1182/blood-2009-12-260976.
9. De Laat B., Derksen R.H.W.M., van Lummel M., Pennings M.T.T., De Groot P.G. Pathogenic anti - beta 2 -glycoprotein I antibodies recognize domain I of beta 2 -glycoprotein I only after a conformational change. Hemost Thromb Vasc Biol 2006, 107:1916-1924.
10. De Laat B.H., Derksen R.H.W.M., Urbanus R.T., Roest M., De Groot P.G. B2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 2004, 104:3598-3602. 10.1182/blood-2004-03-1107.
11. Ruffatti A., Tonello M., Del Ross T., Cavazzana A., Grava C., Noventa F., et al. Antibody profile and clinical course in primary antiphospholipid syndrome with pregnancy morbidity. Thromb Haemost 2006, 96:337-341. 10.1160/TH06-05-0287.
12. Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003, 101:1827-1832. 10.1182/blood-2002-02-0441.
13. Opatrny L., David M., Kahn S.R., Shrier I., Rey E. Association between antiphospholipid antibodies and recurrent fetal loss in women without autoimmune disease: a metaanalysis. J Rheumatol 2006, 33:2214-2221.
14. Lockshin M.D., Kim M., Laskin C.A., Guerra M., Branch D.W., Merrill J., et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012, 64:2311-2318. 10.1002/art.34402.
15. Pengo V., Ruffatti A., Legnani C., Gresele P., Barcellona D., Erba N., et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010, 8:237-242. 10.1111/j.1538-7836.2009.03674.x.
16. Pengo V., Ruffatti A., Legnani C., Testa S., Fierro T., Marongiu F., et al. Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study. Blood 2011, 118:4714-4718. 10.1182/blood-2011-03-340232.
17. Alijotas-Reig J., Ferrer-Oliveras R., Ruffatti A., Tincani A., Lefkou E., Bertero M.T., et al. The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): a survey of 247 consecutive cases. Autoimmun Rev 2014, 14:387-395. 10.1016/j.autrev.2014.12.010.
18. Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011, 7:330-339. 10.1038/nrrheum.2011.52.
19. Arad A., Proulle V., Furie R.A., Furie B.C., Furie B. β2-Glycoprotein-1 autoantibodies from patients with antiphospholipid syndrome are sufficient to potentiate arterial thrombus formation in a mouse model. Blood 2011, 117:3453-3459. 10.1182/blood-2010-08-300715.
20. Pericleous C., Ruiz-Limon P., Romay-Penabad Z., Carrera Marin A., Garza-Garcia A., Murfitt L., et al. Proof-of-concept study demonstrating the pathogenicity of affinity-purified IgG antibodies directed to domain I of 2-glycoprotein I in a mouse model of anti-phospholipid antibody-induced thrombosis. Rheumatology 2014, 54:722-727. 10.1093/rheumatology/keu360.
21. Girardi G., Berman J., Redecha P., Spruce L., Thurman J.M., Kraus D., et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003, 112:1644-1654. 10.1172/JCI200318817.
22. Willis R., Gonzalez E.B., Brasier A.R. The journey of antiphospholipid antibodies from cellular activation to antiphospholipid syndrome. Curr Rheumatol Rep 2015, 17:1-11. 10.1007/s11926-014-0485-9.
23. Viall C.A., Chamley L.W. Histopathology in the placentae of women with antiphospholipid antibodies: a systematic review of the literature. Autoimmun Rev 2015, 14:1-20. 10.1016/j.autrev.2015.01.008.
24. Tong M., Viall C.A., Chamley L.W. Antiphospholipid antibodies and the placenta: a systematic review of their in vitro effects and modulation by treatment. Hum Reprod Update 2014, 21:97-118. 10.1093/humupd/dmu049.
25. Exner T., Barber S., Kronenberg H., Rickard K.A. Familial association of the lupus anticoagulant. Br J Haematol 1980, 45:89-96.
26. Matthey F., Walshe K., Mackie I.J., Machin S.J. Familial occurrence of the antiphospholipid syndrome. J Clin Pathol 1989, 42:495-497.
27. Ford P.M., Brunet D., Lillicrap D.P., Ford S.E. Premature stroke in a family with lupus anticoagulant and antiphospholipid antibodies. Stroke 1990, 21:66-71.
28. Soriano A., Blank M., Shoenfeld Y. Genetics and origin of antiphospholipid syndrome. Antiphospholipid antibody syndrome from bench to bedside 2015, 1-12. Springer. 1st ed. P.L. Meroni (Ed.).
29. Tanimura K., Jin H., Suenaga T., Morikami S., Arase N., Kishida K., et al. β2-Glycoprotein I/HLA class II complexes are novel autoantigens in antiphospholipid syndrome. Blood 2015, 125:2835-2844. 10.1182/blood-2014-08-593624.K.
30. Domenico Sebastiani G., Minisola G., Galeazzi M. HLA class II alleles and genetic predisposition to the antiphospholipid syndrome. Autoimmun Rev 2003, 2:387-394.
31. Yin H., Borghi M.O., Delgado-Vega A.M., Tincani A., Meroni P.L., Alarcón-Riquelme M.E. Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome. Arthritis Rheum 2009, 60:2468-2471. 10.1002/art.24701.
32. Fredi M., Tincani A., Yin H., Delgado-Vega A., Borghi M.O. IRF5 is associated with primary antiphospholipid syndrome, but is not a major risk factor. Arthritis Rheum 2010, 62:1201. 10.1002/art.27341.
33. Horita T., Atsumi T., Yoshida N., Nakagawa H., Kataoka H., Yasuda S., et al. STAT4 single nucleotide polymorphism, rs7574865 G/T, as a risk for antiphospholipid syndrome. Ann Rheum Dis 2009, 68:1366-1367. 10.1136/ard.2008.094367.
34. Sigurdsson S., Nordmark G., Goring H.H., Lindroos K., Wiman A.C., Sturfelt G., et al. Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. Am J Hum Genet 2005, 76:528-537. 10.1086/428480.
35. Remmers E.F., Plenge R.M., Lee A.T., Graham R.R., Hom G., Behrens T.W., et al. STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 2007, 357:977-986. 10.1056/NEJMoa073003.
36. Hom G., Ph D., Graham R.R., Modrek B., Taylor K.E., Ortmann W., et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008, 358:900-909.
37. Chamorro A.-J., Marcos M., Mirón-Canelo J.-A., Cervera R., Espinosa G. Val247Leu beta2-glycoprotein-I allelic variant is associated with antiphospholipid syndrome: systematic review and meta-analysis. Autoimmun Rev 2012, 11:705-712. 10.1016/j.autrev.2011.12.006.
38. Kamboh M.I., Wang X., Kao A.H., Barmada M.M., Clarke A., Ramsey-goldman R., et al. Genome-wide association study of antiphospholipid antibodies. Autoimmune Dis 2013, 2013.
39. Pierangeli S.S., Vega-Ostertag M.E., Raschi E., Liu X., Romay-Penabad Z., De Micheli V., et al. Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies. Ann Rheum Dis 2007, 66:1327-1333. 10.1136/ard.2006.065037.
40. Atsumi T., Caliz R., Amengual O., Khamashta M.A., Hughes G.R. Fcgamma receptor IIA H/R131 polymorphism in patients with antiphospholipid antibodies. Thromb Haemost 1998, 79:924-927.
41. Karassa F.B., Bijl M., Davies K.A., Kallenberg C.G.M., Khamashta M.A., Manger K., et al. Role of the Fcγ receptor IIA polymorphism in the antiphospholipid syndrome: an international meta-analysis. Arthritis Rheum 2003, 48:1930-1938. 10.1002/art.11059.
42. Kato M., Atsumi T., Oku K., Amengual O., Nakagawa H., Fujieda Y., et al. The involvement of CD36 in monocyte activation by antiphospholipid antibodies. Lupus 2013, 22:761-771. 10.1177/0961203313490242.
43. Bertolaccini M.L., Atsumi T., Lanchbury J.S., Caliz A.R., Katsumata K., Vaughan R.W., et al. Plasma tumor necrosis factor alpha levels and the -238*A promoter polymorphism in patients with antiphospholipid syndrome. Thromb Haemost 2001, 85:198-203.
44. Hiddink L., de Laat B., Derksen R.H.W.M., de Groot P.G., van Heerde W.L. Annexin A5 haplotypes in the antiphospholipid syndrome. Thromb Res 2015, 135:417-419. 10.1016/j.thromres.2014.12.004.
45. De Laat B., Derksen R.H.W.M., Mackie I.J., Roest M., Schoormans S., Woodhams B.J., et al. Annexin A5 polymorphism (-1C-->T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome. Ann Rheum Dis 2006, 65:1468-1472. 10.1136/ard.2005.045237.
46. Yonal I., Hindilerden F., Hancer V.S., Artim-Esen B., Daglar A., Akadam B., et al. The impact of platelet membrane glycoprotein Ib alpha and Ia/IIa polymorphisms on the risk of thrombosis in the antiphospholipid syndrome. Thromb Res 2012, 129:486-491. 10.1016/j.thromres.2011.10.005.
47. Jiménez S., Tàssies D., Espinosa G., García-Criado A., Plaza J., Monteagudo J., et al. Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus. Ann Rheum Dis 2008, 67:835-840. 10.1136/ard.2007.077321.
48. Diz-Kucukkaya R., Inanc M., Afshar-Kharghan V., Zhang Q.E., López J.A., Pekcelen Y. P-selectin glycoprotein ligand-1 VNTR polymorphisms and risk of thrombosis in the antiphospholipid syndrome. Ann Rheum Dis 2007, 66:1378-1380. 10.1136/ard.2007.075945.
49. Castro-Marrero J., Balada E., Vilardell-Tarrés M., Ordi-Ros J. Genetic risk factors of thrombosis in the antiphospholipid syndrome. Br J Haematol 2009, 147:289-296. 10.1111/j.1365-2141.2009.07831.x.
50. Gustafsson J.T., Gunnarsson I., Källberg H., Pettersson S., Zickert A., Vikerfors A., et al. Cigarette smoking, antiphospholipid antibodies and vascular events in Systemic Lupus Erythematosus. Ann Rheum Dis 2014, 74:1537-1543. 10.1136/annrheumdis-2013-205159.
51. Gharavi A.E., Pierangeli S.S., Espinola R.G., Liu X., Colden-Stanfield M., Harris E.N. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum 2002, 46:545-552. 10.1002/art.10130.
52. Blank M., Krause I., Fridkin M., Keller N., Kopolovic J., Goldberg I., et al. Bacterial induction of autoantibodies to B2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002, 109:797-804. 10.1172/JCI200212337.
53. Van Os G.M.A., Meijers J.C.M., Agar Ç., Seron M.V., Marquart J.A., Åkesson P., et al. Induction of anti-β 2-glycoprotein I autoantibodies in mice by protein H of Streptococcus pyogenes. J Thromb Haemost 2011, 9:2447-2456. 10.1111/j.1538-7836.2011.04532.x.
54. Dzionek A., Fuchs A., Schmidt P., Cremer S., Zysk M., Miltenyi S., et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J Immunol 2000, 165:6037-6046. 10.4049/jimmunol.165.11.6037.
55. Kool M., van Loo G., Waelput W., De Prijck S., Muskens F., Sze M., et al. The ubiquitin-editing protein A20 prevents dendritic cell activation, recognition of apoptotic cells, and systemic autoimmunity. Immunity 2011, 35:82-96. 10.1016/j.immuni.2011.05.013.
56. Bondanza A., Rovere-Querini P., Zimmermann V.S., Balestrieri G., Tincani A., Sabbadini M.G., et al. Requirement for dendritic cells in the establishment of anti-phospholipid antibodies. Autoimmunity 2007, 40:302-306. 10.1080/08916930701356572.
57. Bondanza A., Zimmermann V.S., Dell'Antonio G., Dal Cin E., Balestrieri G., Tincani A., et al. Requirement of dying cells and environmental adjuvants for the induction of autoimmunity. Arthritis Rheum 2004, 50:1549-1560. 10.1002/art.20187.
58. Kuwana M., Matsuura E., Kobayashi K., Okazaki Y., Kaburaki J., Ikeda Y., et al. Binding of beta 2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood 2005, 105:1552-1557. 10.1182/blood-2004-08-3145.
59. Yamaguchi Y., Seta N., Kaburaki J., Kobayashi K., Matsuura E., Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to beta(2)-glycoprotein I in patients with antiphospholipid syndrome. Blood 2007, 110:4312-4318. 10.1182/blood-2007-07-100008.
60. Rovere P., Sabbadini M.G., Vallinoto C., Fascio U., Rescigno M., Crosti M., et al. Dendritic cell presentation of antigens from apoptotic cells in a proinflammatory context: role of opsonizing anti-2-glycoprotein I antibodies. Arthritis Rheum 1999, 42:1412-1420.
61. Rovere P., Manfredi A.A., Vallinoto C., Zimmermann V.S., Fascio U., Balestrieri G., et al. Dendritic cells preferentially internalize apoptotic cells opsonized by anti-2-glycoprotein I antibodies. J Autoimmun 1998, 11:403-411.
62. Arbuckle M., McClain M., Rubertone M., Scofield R., Dennis G., James J., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003, 349:1526-1533. 10.1056/NEJM200401153500320.
63. Levine J.S., Subang R., Nasr S.H., Fournier S., Lajoie G., Wither J., et al. Immunization with an apoptotic cell-binding protein recapitulates the nephritis and sequential autoantibody emergence of systemic lupus erythematosus. J Immunol 2006, 177:6504-6516. 10.4049/jimmunol.177.9.6504.
64. Ara F.D., Reggia R., Taraborelli M., Andreoli L., Taglietti M., Frassi M., et al. Patients with longstanding primary antiphospholipid syndrome: retrospective analysis of organ damage and mortality. Lupus 2014, 23:1255-1258.
65. Petri M. Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort. Lupus 2010, 19:419-423. 10.1177/0961203309360541.
66. Ioannou Y., Zhang J.-Y., Qi M., Gao L., Qi J.C., Yu D.-M., et al. Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen β2-glycoprotein I. Arthritis Rheum 2011, 63:2774-2782. 10.1002/art.30383.
67. Buttari B., Profumo E., Mattei V., Siracusano A., Ortona E., Margutti P., et al. Oxidized beta2-glycoprotein I induces human dendritic cell maturation and promotes a T helper type 1 response. Blood 2005, 106:3880-3887. 10.1182/blood-2005-03-1201.
68. + T cell response to β2GPI. Ann Rheum Dis 2012, 71:120-128. 10.1136/annrheumdis-2011-200063.
69. Swiecki M., Colonna M. The multifaceted biology of plasmacytoid dendritic cells. Nat Rev Immunol 2015, 15:471-485. 10.1038/nri3865.
70. Gilliet M., Cao W., Liu Y.-J. Plasmacytoid dendritic cells: sensing nucleic acids in viral infection and autoimmune diseases. Nat Rev Immunol 2008, 8:594-606. 10.1038/nri2358.
71. Bennett L., Palucka A.K., Arce E., Cantrell V., Borvak J., Banchereau J., et al. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 10.1084/jem.20021553.
72. Baechler E.C., Batliwalla F.M., Karypis G., Gaffney P.M., Ortmann W.A., Espe K.J., et al. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003, 100:2610-2615. 10.1073/pnas.0337679100.
73. Higgs B.W., Liu Z., White B., Zhu W., White W.I., Morehouse C., et al. Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway. Ann Rheum Dis 2011, 70:2029-2036. 10.1136/ard.2011.150326.
74. Eloranta M.-L., Alm G.V., Rönnblom L. Disease mechanisms in rheumatology--tools and pathways: plasmacytoid dendritic cells and their role in autoimmune rheumatic diseases. Arthritis Rheum 2013, 65:853-863. 10.1002/art.37821.
75. Bernales I., Fullaondo A., Marín-Vidalled M.J., Ucar E., Martínez-Taboada V., López-Hoyos M., et al. Innate immune response gene expression profiles characterize primary antiphospholipid syndrome. Genes Immun 2008, 9:38-46. 10.1038/sj.gene.6364443.
76. Perez-Sanchez C., Barbarroja N., Messineo S., Ruiz-Limon P., Rodriguez-Ariza A., Jimenez-Gomez Y., et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus. Ann Rheum Dis 2015, 74(7):1441-1449. 10.1136/annrheumdis-2013-204600.
77. Crow M.K. Type I interferon in the pathogenesis of lupus. J Immunol 2014, 192:5459-5468. 10.4049/jimmunol.1002795.
78. Prinz N., Clemens N., Strand D., Pütz I., Lorenz M., Daiber A., et al. Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells. Blood 2011, 118:2322-2332. 10.1182/blood-2011-01-330639.
79. Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., et al. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of IL-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology 2009, 214:683-691. 10.1016/j.imbio.2008.12.003.
80. Aguilar-Valenzuela R., Nickerson K., Romay-Penabad Z., Shlomchik M.J., Vargas G., Shilagard T., et al. Involvement of TLR7 and TLR9 in the production of antiphospholipid antibodies. Arthritis Rheum 2011, 63(Suppl. 1).
81. Becker J.C., Winkler B., Klingert S., Bröcker E.B. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. Cancer 1994, 73:1621-1624.
82. Stavropoulou-giokas C., Frangia K., Markopoulos C., Bafaloukos D., Pectasides D., Fountzilas G., et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006, 354:709-718.
83. Kuznik A., Bencina M., Svajger U., Jeras M., Rozman B., Jerala R. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines. J Immunol 2011, 186:4794-4804. 10.4049/jimmunol.1000702.
84. Wallace D.J., Gudsoorkar V.S., Weisman M.H., Venuturupalli S.R. New insights into mechanisms of therapeutic effects of antimalarial agents in SLE. Nat Rev Rheumatol 2012, 8:522-533. 10.1038/nrrheum.2012.106.
85. Sacre K., Criswell L.A., McCune J.M. Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus. Arthritis Res Ther 2012, 14:R155. 10.1186/ar3895.
86. Mekinian A., Lazzaroni M.G., Kuzenko A., Alijotas-Reig J., Ruffatti A., Levy P., et al. The efficacy of hydroxychloroquine for obstetrical outcome in anti-phospholipid syndrome: data from a European multicenter retrospective study. Autoimmun Rev 2015, 6-10. 10.1016/j.autrev.2015.01.012.
87. De Carolis S., Botta A., Salvi S., di Pasquo E., Del Sordo G., Garufi C., et al. Is there any role for the hydroxychloroquine (HCQ) in refractory obstetrical antiphospholipid syndrome (APS) treatment?. Autoimmun Rev 2015, 14:760-762. 10.1016/j.autrev.2015.04.010.
88. Schmidt-Tanguy A., Voswinkel J., Henrion D., Subra J., Loufrani L., Rohmer V., et al. Anti-thrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost 2013, 11:1927-1929. 10.1111/jth.12363.
89. Belizna C. Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome. Autoimmun Rev 2015, 14:358-362. 10.1016/j.autrev.2014.12.006.
90. Comarmond C., Cacoub P. Antiphospholipid syndrome: from pathogenesis to novel immunomodulatory therapies. Autoimmun Rev 2013, 12:752-757. 10.1016/j.autrev.2012.12.006.
91. Kuwana M. Autoreactive CD4 T cells to b 2-glycoprotein I in patients with antiphospholipid syndrome. Autoimmun Rev 2003, 2:192-198. 10.1016/S1568-9972.
92. Kuwana M. Beta2-glycoprotein I: antiphospholipid syndrome and T-cell reactivity. Thromb Res 2004, 114:347-355. 10.1016/j.thromres.2004.06.029.
93. Hattori N., Kuwana M., Kaburaki J., Mimori T., Ikeda Y., Kawakami Y. T cells that are autoreactive to beta2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis Rheum 2000, 43:65-75. 10.1002/1529-0131(200001)43:1<65::AID-ANR9>3.0.CO;2-I.
94. Arai T., Yoshida K., Kaburaki J., Inoko H., Ikeda Y., Kawakami Y., et al. Autoreactive CD4+ T-cell clones to beta2-glycoprotein I in patients with antiphospholipid syndrome: preferential recognition of the major phospholipid-binding site. Blood 2001, 98:1889-1896. 10.1182/blood.V98.6.1889.
95. Yoshida K., Arai T., Kaburaki J., Ikeda Y., Kawakami Y., Kuwana M. Restricted T-cell receptor beta-chain usage by T cells autoreactive to beta 2-glycoprotein I in patients with antiphospholipid syndrome. Blood 2002, 99:2499-2504. 10.1182/blood.V99.7.2499.
96. Visvanathan S., McNeil H.P. Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome. J Immunol 1999, 162:6919-6925.
97. Davies M.L., Young S.P., Welsh K., Bunce M., Wordsworth B.P., Davies K.A., et al. Immune responses to native beta(2)-glycoprotein I in patients with systemic lupus erythematosus and the antiphospholipid syndrome. Rheumatology (Oxford) 2002, 41:395-400.
98. Conti F., Spinelli F.R., Alessandri C., Pacelli M., Ceccarelli F., Marocchi E., et al. Subclinical atherosclerosis in systemic lupus erythematosus and antiphospholipid syndrome: focus on β2GPI-specific T cell response. Arterioscler Thromb Vasc Biol 2014, 34:661-668. 10.1161/ATVBAHA.113.302680.
99. Grant C.R., Liberal R., Mieli-Vergani G., Vergani D., Longhi M.S. Regulatory T-cells in autoimmune diseases: challenges, controversies and-yet-unanswered questions. Autoimmun Rev 2015, 14:105-116. 10.1016/j.autrev.2014.10.012.
100. Singh R.P., Hasan S., Sharma S., Nagra S., Yamaguchi D.T., Wong D.T., et al. Th17 cells in inflammation and autoimmunity. Autoimmun Rev 2014, 13:1174-1181. 10.1016/j.autrev.2014.08.019.
101. Noack M., Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Rev 2014, 13:668-677. 10.1016/j.autrev.2013.12.004.
102. Karakantza M., Theodorou G.L., Meimaris N., Mouzaki A., John E., Andonopoulos A.P., et al. Type 1 and type 2 cytokine-producing CD4+ and CD8+ T cells in primary antiphospholipid syndrome. Ann Hematol 2004, 83:704-711. 10.1007/s00277-004-0910-7.
103. Papo T., Piette J.C., Legac E., Frances C., Grenot P., Debre P., et al. T lymphocyte subsets in primary antiphospholipid syndrome. J Rheumatol 1994, 21:2242-2245.
104. Ames P., Tommasino C., Fossati G., Matsuura E., Margarita A., Saulino A., et al. Lymphocyte subpopulations and intima media thickness in primary antiphospholipd syndrome. Lupus 2005, 14:809-813. 10.1191/0961203305lu2181oa.
105. Carbone J., Gallego A., Lanio N., Navarro J., Orera M., Aguaron A., et al. Quantitative abnormalities of peripheral blood distinct T, B, and natural killer cell subsets and clinical findings in obstetric antiphospholipid syndrome. J Rheumatol 2009, 36:1217-1225. 10.3899/jrheum.081079.
106. Ito H., Matsushita S., Tokano Y., Nishimura H., Tanaka Y., Fujisao S., et al. Analysis of T cell responses to the beta 2-glycoprotein I-derived peptide library in patients with anti-beta 2-glycoprotein I antibody-associated autoimmunity. Hum Immunol 2000, 61:366-377.
107. Forestiero R. Imbalance towards Th2-type response in patients with definite primary antiphospholipid syndrome. Thromb Haemost 2001, 453:934-935.
108. Soltesz P., Der H., Veres K., Laczik R., Sipka S., Szegedi G., et al. Immunological features of primary anti-phospholipid syndrome in connection with endothelial dysfunction. Rheumatology (Oxford) 2008, 47:1628-1634. 10.1093/rheumatology/ken349.
109. Popovic-Kuzmanovic D., Novakovic I., Stojanovich L., Aksentijevich I., Zogovic N., Tovilovic G., et al. Increased activity of interleukin-23/interleukin-17 cytokine axis in primary antiphospholipid syndrome. Immunobiology 2013, 218:186-191. 10.1016/j.imbio.2012.03.002.
110. Xiao J., Zhu F., Liu X., Xiong J. Th1/Th2/Th17/Treg expression in cultured PBMCs with antiphospholipid antibodies. Mol Med Rep 2012, 6:1035-1039. 10.3892/mmr.2012.1055.
111. Dal Ben E.R.R., do Prado C.H., Baptista T.S.A., Bauer M.E., Staub H.L. Decreased levels of circulating CD4+CD25+Foxp3+ regulatory T cells in patients with primary antiphospholipid syndrome. J Clin Immunol 2013, 33:876-879. 10.1007/s10875-012-9857-y.
112. Soroka N., Talako T., Smolnikova V. THU0504 regulatory T cells in peripheral blood of patients with antiphospholipid syndrome. Ann Rheum Dis 2014, 73:357-358. (SUPPL. 2). 10.1136/annrheumdis-2014-eular.4485.
113. Staub H.L., Dal Ben E.R.R., Bauer M.E. The antiphospholipid syndrome and Tregs. Autoimmun Rev 2014, 13:697-698. 10.1016/j.autrev.2013.08.004.
114. Dal Ben E.R.R.D., Do Prado C.H., Baptista T.S.A., Bauer M.E., Staub H.L. Patients with systemic lupus erythematosus and secondary antiphospholipid syndrome have decreased numbers of circulating CD4+CD25+Foxp3+ Treg and CD3- CD19+ B cells. Rev Bras Reumatol (English Ed) 2014, 54:241-246. 10.1016/j.rbre.2013.09.001.
115. Lai Z., Marchena-Mendez I., Perl A. Oxidative stress and Treg depletion in lupus patients with anti-phospholipid syndrome. Clin Immunol 2015, 158:148-152. 10.1016/j.clim.2015.03.024.
116. Mahmoud F., Diejomaoh M., Omu A.E., Abul H., Haines D. Lymphocyte subpopulation frequency and presence of anti-cardiolipin and anti-nuclear antibodies in peripheral blood of Kuwaiti women experiencing recurrent pregnancy loss. J Obstet Gynaecol 2001, 21:587-590. 10.1080/01443610120087805.
117. Velasquillo M.C., Alcocer-Varela J., Alarcón-Segovia D., Cabiedes J., Sánchez-Guerrero J. Some patients with primary antiphospholipid syndrome have increased circulating CD5+ B cells that correlate with levels of IgM antiphospholipid antibodies. Clin Exp Rheumatol 1991, 9:501-505.
118. Simonin L., Pasquier E., Leroyer E., Cornec D., Bendaoud B., Hillion S., et al. Among patients with venous thrombo-embolism, B cell subset disturbances characterise those with primary antiphospholipid syndrome. Ann Rheum Dis 2015, 74(Suppl. 2):572.
119. Sigal L.H. Basic science for the clinician 49. J Clin Rheumatol 2009, 15:90-94. 10.1097/RHU.0b013e31819c3a49.
120. Lieby P., Soley A., Knapp A.-M., Cerutti M., Freyssinet J.-M., Pasquali J.-L., et al. Memory B cells producing somatically mutated antiphospholipid antibodies are present in healthy individuals. Blood 2003, 102:2459-2465. 10.1182/blood-2003-01-0180.
121. Kahn P., Ramanujam M., Bethunaickan R., Huang W., Madaio M.P., Factor S.M., et al. Prevention of murine antiphospholipid syndrome by BAFF blockade. Arthritis Rheum 2008, 58:2824-2834. 10.1002/art.23764.Prevention.
122. Berman H., Rodríguez-Pintó I., Cervera R., Morel N., Costedoat-Chalumeau N., Erkan D., et al. Rituximab use in the catastrophic antiphospholipid syndrome: descriptive analysis of the CAPS registry patients receiving rituximab. Autoimmun Rev 2013, 12:1085-1090. 10.1016/j.autrev.2013.05.004.
123. Erkan D., Vega J., Ramón G., Kozora E., Lockshin M.D. A pilot open-label phase II trial of rituximab for non-criteria manifestations of antiphospholipid syndrome. Arthritis Rheum 2013, 65:464-471. 10.1002/art.37759.
124. López-Pedrera C., Buendía P., Cuadrado M.J., Siendones E., Aguirre M.A., Barbarroja N., et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-activated protein kinase pathway, and of the MEK-1/ERK. Arthritis Rheum 2006, 54:301-311. 10.1002/art.21549.
125. Sorice M., Longo A., Capozzi A., Garofalo T., Misasi R., Alessandri C., et al. Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. Arthritis Rheum 2007, 56:2687-2697. 10.1002/art.22802.
126. Lambrianides A., Carroll C.J., Pierangeli S.S., Pericleous C., Branch W., Rice J., et al. Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathways. J Immunol 2010, 184:6622-6628. 10.4049/jimmunol.0902765.
127. Xie H., Zhou H., Wang H., Chen D., Xia L., Wang T., et al. Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. Mol Immunol 2013, 53:246-254. 10.1016/j.molimm.2012.08.012.
128. Colasanti T., Alessandri C., Capozzi A., Sorice M., Delunardo F., Longo A., et al. Autoantibodies specific to a peptide of β2-glycoprotein I cross-react with TLR4, inducing a proinflammatory phenotype in endothelial cells and monocytes. Blood 2012, 120:3360-3370. 10.1182/blood-2011-09-378851.
129. Zhou H., Ling S., Yu Y., Wang T., Hu H. Involvement of annexin A2 in anti-beta2GPI/beta2GPI-induced tissue factor expression on monocytes. Cell Res 2007, 17:737-739. 10.1038/cr.2007.33.
130. López-Pedrera C., Cuadrado M.J., Herández V., Buendïa P., Aguirre M.A., Barbarroja N., et al. Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis. Arthritis Rheum 2008, 58:2835-2844. 10.1002/art.23756.
131. Satta N., Kruithof E.K.O., Fickentscher C., Dunoyer-Geindre S., Boehlen F., Reber G., et al. Toll-like receptor 2 mediates the activation of human monocytes and endothelial cells by antiphospholipid antibodies. Blood 2011, 117:5523-5531. 10.1182/blood-2010-11-316158.
132. Brandt K.J., Fickentscher C., Boehlen F., Kruithof E.K.O., de Moerloose P. NF-κB is activated from endosomal compartments in antiphospholipid antibodies-treated human monocytes. J Thromb Haemost 2014, 12:779-791. 10.1111/jth.12536.
133. Döring Y., Hurst J., Lorenz M., Prinz N., Clemens N., Drechsler M.D., et al. Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. Immunobiology 2010, 215:230-241. 10.1016/j.imbio.2009.03.002.
134. Kornberg A., Blank M., Susana K., Yehuda S. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 1994, 153:1328-1332.
135. Cuadrado M.J., López-Pedrera C., Khamashta M.A., Camps M.T., Tinahones F., Torres A., et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum 1997, 40:834-841. 10.1002/1529-0131(199705)40:5<834::AID-ART8>3.0.CO;2-#.
136. Reverter J., Tassies D., Font J., Khamashta M.A., Ichikawa J., Cervera R., et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum 1998, 41:1420-1427.
137. Dobado-Berrios P.M., López-Pedrera C., Velasco F., Aguirre M.A., Torres A., Cuadrado M.J. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost 1999, 82:1578-1582.
138. Zhou H., Wolberg A.S., Roubey R.A.S. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood 2004, 104:2353-2358. 10.1182/blood-2004-01-0145.
139. Cuadrado M.J., Buendía P., Velasco F., Aguirre M.A., Barbarroja N., Torres L.A., et al. Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome. J Thromb Haemost 2006, 4:2461-2469. 10.1111/j.1538-7836.2006.02193.x.
140. López-Pedrera C., Aguirre M.A., Buendía P., Barbarroja N., Ruiz-Limón P., Collantes-Estevez E., et al. Differential expression of protease-activated receptors in monocytes from patients with primary antiphospholipid syndrome. Arthritis Rheum 2010, 62:869-877. 10.1002/art.27299.
141. Xia L., Zhou H., Hu L., Xie H., Wang T., Xu Y., et al. Both NF-κB and c-Jun/AP-1 involved in anti-β2GPI/β2GPI-induced tissue factor expression in monocytes. Thromb Haemost 2013, 109:643-651. 10.1160/TH12-09-0655.
142. Nagahama M., Nomura S., Kanazawa S., Ozaki Y., Kagawa H., Fukuhara S. Significance of anti-oxidized LDL antibody and monocyte-derived microparticles in anti-phospholipid antibody syndrome. Autoimmunity 2003, 36:125-131. 10.1080/0891693031000079257.
143. Vikerfors A., Mobarrez F., Bremme K., Holmström M., Ågren A., Eelde A., et al. Studies of microparticles in patients with the antiphospholipid syndrome (APS). Lupus 2012, 21:802-805. 10.1177/0961203312437809.
144. Chaturvedi S., Cockrell E., Espinola R., Hsi L., Fulton S., Khan M., et al. Circulating microparticles in patients with antiphospholipid antibodies: characterization and associations. Thromb Res 2015, 135:102-108. 10.1016/j.thromres.2014.11.011.
145. Perez-Sanchez C., Ruiz-Limon P., Aguirre M.A., Bertolaccini M.L., Khamashta M.A., Rodriguez-Ariza A., et al. Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment. Blood 2012, 119:5859-5870. 10.1182/blood-2011-12-400986.
146. Bohgaki M., Atsumi T., Yamashita Y., Yasuda S., Sakai Y., Furusaki A., et al. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2Glycoprotein I antibodies. Int Immunol 2004, 16:1633-1641. 10.1093/intimm/dxh166.
147. Kubota T., Fukuya Y., Hashimoto R., Kanda T., Suzuki H., Okamura Y., et al. Possible involvement of chemokine-induced platelet activation in thrombophilic diathesis of antiphospholipid syndrome. Ann N Y Acad Sci 2009, 1173:137-145. 10.1111/j.1749-6632.2009.04648.x.
148. Williams F.M., Jurd K., Hughes G.R.H.B. Antiphospholipid syndrome patients' monocytes are "primed " to express tissue factor. Thromb Haemost 1998, 80:864-865.
149. Ferro D., Saliola M., Meroni P.L., Valesini G., Caroselli C., Praticò D., et al. Enhanced monocyte expression of tissue factor by oxidative stress in patients with antiphospholipid antibodies: effect of antioxidant treatment. J Thromb Haemost 2003, 1:523-531.
150. Teruel R., Pérez-Sánchez C., Corral J., Herranz M.T., Pérez-Andreu V., Saiz E., et al. Identification of miRNAs as potential modulators of tissue factor expression in patients with systemic lupus erythematosus and antiphospholipid syndrome. J Thromb Haemost 2011, 9:1985-1992. 10.1111/j.1538-7836.2011.04451.x.
151. Martirosyan A., Petrek M., Navratilova Z., Blbulyan A., Boyajyan A., Manukyan G. Differential regulation of proinflammatory mediators following LPS- and ATP-induced activation of monocytes from patients with antiphospholipid syndrome. Biomed Res Int 2015, 2015:292851. 10.1155/2015/292851.
152. Müller-calleja N., Köhler A., Siebald B., Canisius A., Orning C., Radsak M., et al. Cofactor-independent antiphospholipid antibodies activate the NLRP3-inflammasome via endosomal NADPH-oxidase: implications for the antiphospholipid syndrome. Thromb Haemost. 2015, 113(5):1071-1083. 10.1160/TH14-07-0628.
153. Lopez-Pedrera C., Perez-Sanchez C., Zamorano A., Barbarroja N., Ruiz-Limon P., Jimenez Gomez Y., et al. Beneficial effects of in vivo ubiquinol supplementation on ethero-thrombosis prevention in antiphospholipid syndrome patients. Arthritis Rheumatol (Hoboken, NJ) 2014, 66. (SUPPL. 10, S4).
154. Erkan D., Willis R., Murthy V.L., Basra G., Vega J., Ruiz-Limón P., et al. A prospective open-label pilot study of fluvastatin on proinflammatory and prothrombotic biomarkers in antiphospholipid antibody positive patients. Ann Rheum Dis 2014, 73:1176-1180. 10.1136/annrheumdis-2013-203622.
155. López-Pedrera C., Ruiz-Limón P., Aguirre M.Á., Barbarroja N., Pérez-Sánchez C., Buendía P., et al. Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome. Ann Rheum Dis 2011, 70:675-682. 10.1136/ard.2010.135525.
156. Newby L.K., Marber M.S., Melloni C., Sarov-Blat L., Aberle L.H., Aylward P.E., et al. Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet 2014, 384:1187-1195. 10.1016/S0140-6736(14)60417-7.
157. Perez-Sanchez C., Ruiz-Limon P., Aguirre M.A., Carretero R.M., Barbarroja N., Collantes E., et al. Characterization of micrornas involved in the regulation of atherotrhombosis in antiphospholipid syndrome and systemic lupus erythematosus. Ann Rheum Dis 2014, 73(Suppl. 2).
158. Arvieux J., Jacob M.-C., Roussel B., Bensa J.-C., Colomb M. Neutrophil antibodies activation by anti-B2 glycoprotein I monoclonal antibodies via Fcg receptor II. J Leukoc Biol 1995, 57:387-394.
159. Gladigau G., Haselmayer P., Scharrer I., Munder M., Prinz N., Lackner K., et al. A role for Toll-like receptor mediated signals in neutrophils in the pathogenesis of the anti-phospholipid syndrome. PLoS One 2012, 7. 10.1371/journal.pone.0042176.
160. Redecha P., Franzke C., Ruf W., Mackman N., Girardi G. Neutrophil activation by the tissue factor / Factor VIIa / PAR2 axis mediates fetal death in a mouse model of antiphospholipid syndrome. J Clin Invest 2008, 118:3453-3461. 10.1172/JCI36089.loss.
161. Ritis K., Doumas M., Mastellos D., Micheli A., Giaglis S., Magotti P., et al. A novel C5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J Immunol 2006, 177:4794-4802.
162. Redecha P., Tilley R., Tencati M., Salmon J.E., Kirchhofer D., Mackman N., et al. Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody-induced fetal injury. Blood 2007, 110:2423-2431. 10.1182/blood-2007-01-070631.
163. Lande R., Ganguly D., Facchinetti V., Frasca L., Conrad C., Gregorio J., et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra19. 10.1126/scitranslmed.3001180.
164. Garcia-Romo G.S., Caielli S., Vega B., Connolly J., Allantaz F., Xu Z., et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011, 3:73ra20. 10.1126/scitranslmed.3001201.
165. Villanueva E., Yalavarthi S., Berthier C.C., Hodgin J.B., Khandpur R., Lin A.M., et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011, 187:538-552. 10.4049/jimmunol.1100450.
166. Van Avondt K., Fritsch-Stork R., Derksen R.H.W.M., Meyaard L. Ligation of signal inhibitory receptor on leukocytes-1 suppresses the release of neutrophil extracellular traps in systemic lupus erythematosus. PLoS One 2013, 8. 10.1371/journal.pone.0078459.
167. Yalavarthi S., Gould T.J., Rao A.N., Mazza L.F., Morris A.E., Núñez-Álvarez C., et al. Antiphospholipid antibodies promote the release of neutrophil extracellular traps: a new mechanism of thrombosis in the antiphospholipid syndrome. Arthritis Rheumatol (Hoboken, NJ) 2015, 10.1002/art.39247.
168. Leffler J., Stojanovich L., Shoenfeld Y., Bogdanovic G., Hesselstrand R., Blom A.M. Degradation of neutrophil extracellular traps is decreased in patients with antiphospholipid syndrome. Clin Exp Rheumatol 2014, 32:66-70.
169. Fuchs T.A., Brill A., Duerschmied D., Schatzberg D., Monestier M., Myers D.D., et al. Extracellular DNA traps promote thrombosis. Proc Natl Acad Sci U S A 2010, 107:15880-15885. 10.1073/pnas.1005743107.
170. Gupta A.K., Hasler P., Holzgreve W., Gebhardt S., Hahn S. Induction of neutrophil extracellular DNA lattices by placental microparticles and IL-8 and their presence in preeclampsia. Hum Immunol 2005, 66:1146-1154. 10.1016/j.humimm.2005.11.003.
171. Shi F.-D., Ljunggren H.-G., La Cava A., Van Kaer L. Organ-specific features of natural killer cells. Nat Rev Immunol 2011, 11:658-671. 10.1038/nri3065.
172. Moffett A., Loke C. Immunology of placentation in eutherian mammals. Nat Rev Immunol 2006, 6:584-594. 10.1038/nri1897.
173. King K., Smith S., Chapman M., Sacks G. Detailed analysis of peripheral blood natural killer (NK) cells in women with recurrent miscarriage. Hum Reprod 2010, 25:52-58. 10.1093/humrep/dep349.
174. Perricone C., De Carolis C., Giacomelli R., Zaccari G., Cipriani P., Bizzi E., et al. High levels of NK cells in the peripheral blood of patients affected with anti-phospholipid syndrome and recurrent spontaneous abortion: a potential new hypothesis. Rheumatology (Oxford) 2007, 46:1574-1578. 10.1093/rheumatology/kem197.
175. Kwak J.Y., Beaman K.D., Gilman-Sachs A., Ruiz J.E., Schewitz D., Beer A.E. Up-regulated expression of CD56+, CD56+/CD16+, and CD19+ cells in peripheral blood lymphocytes in pregnant women with recurrent pregnancy losses. Am J Reprod Immunol 1995, 34:93-99.
176. Heilmann L., Ph D., Schorch M., Hahn T., Adasz G., Schilberz K., et al. Pregnancy outcome in women with antiphospholipid antibodies: report on a retrospective study. Semin Thromb Hemost 2008, 34:794-802. 10.1055/s-0029-1145261.
177. Mariee N.G., Tuckerman E., Laird S., Li T.C. The correlation of autoantibodies and uNK cells in women with reproductive failure. J Reprod Immunol 2012, 95:59-66. 10.1016/j.jri.2012.04.003.
178. Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009, 9:729-740. 10.1038/nri2620.
179. Gropp K., Weber N., Reuter M., Micklisch S., Kopka I., Hallström T., et al. β2-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator. Blood 2011, 118:2774-2783. 10.1182/blood-2011-02-339564.
180. Oku K., Atsumi T., Bohgaki M., Amengual O., Kataoka H., Horita T., et al. Complement activation in patients with primary antiphospholipid syndrome. Ann Rheum Dis 2009, 68:1030-1035. 10.1136/ard.2008.090670.
181. Devreese K.M.J., Hoylaerts M.F. Is there an association between complement activation and antiphospholipid antibody-related thrombosis?. Thromb Haemost 2010, 104:1279-1281. 10.1160/TH10-06-0410.
182. Breen K.A., Seed P., Parmar K., Moore G.W., Stuart-smith S.E., Hunt B.J. Complement activation in patients with isolated antiphospholipid antibodies or primary antiphospholipid syndrome. Thromb Haemost 2012, 107:423-429. 10.1160/TH11-08-0554.
183. Reggia R., Ziglioli T., Andreoli L., Bellisai F., Iuliano A., Gerosa M., et al. Primary anti-phospholipid syndrome: any role for serum complement levels in predicting pregnancy complications?. Rheumatology (Oxford) 2012, 51:2186-2190. 10.1093/rheumatology/kes225.
184. De Carolis S., Botta A., Santucci S., Salvi S., Moresi S., Di Pasquo E., et al. Complementemia and obstetric outcome in pregnancy with antiphospholipid syndrome. Lupus 2012, 21:776-778. 10.1177/0961203312444172.
185. Holers V.M., Girardi G., Mo L., Guthridge J.M., Molina H., Pierangeli S.S., et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002, 195:211-220. 10.1084/jem.200116116.
186. Fischetti F., Durigutto P., Pellis V., Debeus A., Macor P., Bulla R., et al. Thrombus formation induced by antibodies to β2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005, 106:2340-2346. 10.1182/blood-2005-03-1319.
187. Girardi G., Redecha P., Salmon J.E. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004, 10:1222-1226. 10.1038/1121.
188. Erkan D., Aguiar C.L., Andrade D., Cohen H., Cuadrado M.J., Danowski A., et al. 14th International Congress on Antiphospholipid Antibodies: task force report on antiphospholipid syndrome treatment trends. Autoimmun Rev 2014, 13:685-696. 10.1016/j.autrev.2014.01.053.
189. Zhang Z., Zhang R. Epigenetics in autoimmune diseases: pathogenesis and prospects for therapy. Autoimmun Rev 2015, 14:854-863.
190. Broen J.C.A., Radstake T.R.D.J., Rossato M. The role of genetics and epigenetics in the pathogenesis of systemic sclerosis. Nat Rev Rheumatol 2014, 10:671-681. 10.1038/nrrheum.2014.128.
191. Poulton K., Rahman A., Giles I. Examining how antiphospholipid antibodies activate intracellular signaling pathways: a systematic review. Semin Arthritis Rheum 2012, 41:720-736. 10.1016/j.semarthrit.2011.09.004.
192. Du V.X., Kelchtermans H., De Groot P.G., De Laat B. From antibody to clinical phenotype, the black box of the antiphospholipid syndrome: Pathogenic mechanisms of the antiphospholipid syndrome. Thromb Res 2013, 132:319-326. 10.1016/j.thromres.2013.07.023.
193. Brandt K.J., Kruithof E.K.O., de Moerloose P. Receptors involved in cell activation by antiphospholipid antibodies. Thromb Res 2013, 132:408-413. 10.1016/j.thromres.2013.08.015.
194. Ermann J., Rao D.A., Teslovich N.C., Brenner M.B., Raychaudhuri S. Immune cell profiling to guide therapeutic decisions in rheumatic diseases. Nat Rev Rheumatol 2015, 11(9):541-551. 10.1038/nrrheum.2015.71.
195. Jameson J., Longo D. Precision medicine - personalized, problematic, and promising. N Engl J Med 2015, 372:2229-2234.